Published in Blood Weekly, June 23rd, 2005
Erythromycin is an effective treatment for gastroparesis; however, some of its properties, including antibiotic activity, are not appropriate for a drug designed for chronic use over a patient's lifetime. Earlier efforts to produce erythromycin analogs with reduced antibiotic activity resulted in compounds that lost efficacy in repeated dosing regimens (tachyphylaxis). These compounds also blocked in vitro the hERG channel in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.